| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78587acbfc8d4c9e9ac3baa7021087d7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0312
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-706 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8114
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0339
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- |
| filingDate |
2004-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a966e8e9b2a9b9e36a803463c82f054e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_573fbc06957ddb51dfdd191c5df26a87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_384d05e2f4daf3912c4f1217a6ed8161
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_473a4e5b174f16e3cb81cd3fd12a533e |
| publicationDate |
2004-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2520424-A1 |
| titleOfInvention |
Model for neurodegenerative disorders |
| abstract |
The present invention discloses a double transgenic fly that expresses both human Tau protein and the human A.beta.42 peptide of human amyloid-.beta. precursor protein (APP). The double transgenic flies of the present invention display a synergistic altered phenotype as compared to the altered phenotype displayed by transgenic flies expressing either human Tau or human A.beta.42 alone. Thus, the flies provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying therapeutic compounds to treat neurodegenerative disorders using the double transgenic flies. |
| priorityDate |
2003-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |